Erratum corrigé

Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: the randomised JUST-Act study
J.L. Pablos, F. Navarro, F.J. Blanco, J.A. Roman-Ivorra, A. Alonso, E. Martín Mola, M. Cantalejo, on behalf of the study investigators, and L. Ercole, N. Rivero

Published in: Clin Exp Rheumatol 2019; 37: 437-44.

The authors have brought to our attention that there was an error in the Results section on page 440, sub-section Efficacy findings, relating to the p-value given erroneously as \( p=0.007 \) instead of \( p=0.700 \).

The authors would like to point out that the error was due to a typo and does not affect the results or their interpretation and conclusions.

The paragraph containing the error should read as follows:

Switching to TCZ monotherapy was non-inferior to continuing TCZ+MTX for the change in DAS28 at week 28 with an adjusted mean treatment difference of \(-0.06\) (95% CI, \(-0.40\) to \(0.27\); \(p=0.700\)). As the upper limit of the two-sided 95% CI for the difference between treatment groups was \(<0.6\), TCZ monotherapy demonstrated non-inferiority to combination TCZ+MTX.